IDT Australia Ltd Narrows FY26 EBITDA Loss 85% and Targets $50M FY29 Revenue

A turnaround takes shape: IDT narrows FY26 EBITDA loss by 85%

In its August 2026 FY26 full year results presentation, IDT Australia outlined a strategic reset that materially narrowed losses across the reporting period. Management reported an FY26 EBITDA of –$0.9M, an 85% improvement on the FY25 loss of –$6.3M.

Revenue across its three core verticals reached $16.8M, up 16.5% year-on-year, with total revenue including disbursements of $20.4M. The company ended the period with $9.7M in available funds to support its growth agenda.

The presentation framed these results as evidence that IDT’s “profit over revenue” reset is beginning to deliver, positioning the business on a pathway back toward profitability.

FY26 results at a glance

Management presented the following headline financials for the full year, describing the period as a turning point for the business.

The FY26 guidance upgrade published in July 2026 confirmed these headline numbers ahead of the formal results, with management beating its own prior guidance range of -$1.5M to -$2M for EBITDA and clearing the $16M revenue ceiling it had previously set, reinforcing that the full-year result represents a genuine operational beat rather than an end-of-period revision.

The presentation detailed three strategic reset objectives underpinning the result:

• Focus on high-value repeat clients

• Prioritise profit over revenue growth

• Strengthen financial discipline

Management noted approximately $2.5M in FY26 cost savings and improved operating leverage, delivering an 85% EBITDA improvement on 16.5% revenue growth.

Three growth verticals driving the business

IDT highlighted three growth verticals, with the individual revenue splits presented as placeholder figures subject to confirmation.

API manufacturing — revenue up 29% to $5.4M

The active pharmaceutical ingredient (API) business, focused on small-molecule and complex high-potency chemistry, grew 29.4% to $5.4M. Management described it as the foundation business, feeding flow-on work to the other two verticals.

Solid oral manufacturing — revenue up 52% to $5.5M

Solid oral manufacturing recorded the strongest growth, up 51.7% to $5.5M. The presentation pointed to radiopharmaceutical opportunities and demand from medicinal cannabis and psychedelic clients, alongside tablet, capsule and liquid production at scale.

Sterile manufacturing — revenue down 11% to $5.9M

Sterile manufacturing revenue declined 10.8% to $5.9M, which management attributed to the timing of contracts rather than any structural weakness. The presentation emphasised sterile manufacturing remains the key growth driver for the group, supported by mRNA demand and IDT’s Sanofi “Preferred Vendor” status.

The Sanofi Preferred Vendor designation, covered in detail when it was announced in April 2026, unlocked access to bid across multiple Sanofi business units and therapeutic areas, adding a high-profile commercial anchor to the sterile manufacturing pipeline that management now cites as a key growth driver.

What is a CDMO, and why it matters here

A Contract Development & Manufacturing Organisation (CDMO) is an outsourced partner that provides drug development and manufacturing services to pharmaceutical and biotech companies. Rather than build their own facilities, clients contract specialists like IDT to develop and produce their medicines.

The presentation also referenced two market-sizing terms. Total Addressable Market (TAM) is the maximum revenue opportunity if 100% market share were captured. Serviceable Addressable Market (SAM) is the share of that TAM that IDT’s capabilities, capacity and geographic reach can realistically serve.

For investors, management framed IDT as one of few regional CDMOs offering sterile fill alongside full end-to-end services, a scarcity that management suggested supports pricing advantage.

A US$130B market opportunity across three regions

The presentation outlined the addressable market across IDT’s three verticals, spanning the US, EU and APAC regions.

Management put the total SAM at US$130B across the three regions, noting the US is the largest opportunity today, with Europe and APAC offering significant expansion potential. The market sizing was sourced from third-party research, including Mordor Intelligence and Grand View Research.

A $7M funded investment in high-tech capability

The presentation detailed a $7M capital investment across FY27–FY28, which management stated is fully funded via IDT’s existing debt facility, with access to government grant programs supporting Australia’s sovereign manufacturing capabilities.

The investment covers two capability upgrades:

1. A new sterile manufacturing line using Isolator Technology for Grade A aseptic fill-finish. Management described this as enabling commercial-scale fill-finish, serving antibody-drug conjugates (ADCs), biologics, biosimilars, mRNA vaccines and specialty injectables.

2. A solid oral dose upgrade, including a tablet press, coating, solids handling and a complete bottle line. This is intended to unlock more complex modified-release and fixed-dose combination contracts.

Management indicated these upgrades build pricing power given the shortage of qualified CDMOs across these segments.

The pathway to $50M revenue by FY29

The presentation set out the strategic roadmap toward a $50M revenue target by FY29. For FY27, management forecast double-digit revenue growth and a positive EBITDA. The FY29 target equals just 0.027% of the total addressable market management outlined.

Management detailed a five-stage pathway to reach the target:

1. Strategic positioning as a specialist in complex small-molecule API and sterile & non-sterile manufacturing

2. Existing customer expansion, advancing programs from clinical to commercial

3. Strategic account management through proactive planning

4. Market growth and lead generation via targeted channels and events

5. New customer acquisition across the US, Europe and APAC

Management positioned IDT as an agile, specialist CDMO targeting high-value global segments poorly served by competitors, with a fully funded investment program and disciplined financial reset intended to drive the business toward its FY29 revenue target.

Experienced leadership behind the reset

The presentation profiled IDT’s board and leadership, positioning management experience as a key element of the turnaround.

• Mark Simari — Executive Chair/CEO; former managing director and co-founder of Paragon Care (2008–2018).

• Geoffrey Sam, OAM — Non-Executive Director; Chairperson of Earlypay Ltd (ASX:EPY) and co-founder of Healthe Care Australia.

• Dr Jane Ryan — Non-Executive Director; over 30 years of international pharmaceutical and biotechnology experience, and a board member of Neuphoria Therapeutics Inc. (NASDAQ:NEUP).

IDT was also named a winner at the Asia-Pacific RNA Excellence Awards 2026.

Taken together, the presentation set out a funded, disciplined turnaround, with an 85% narrowing of EBITDA losses, a clear $50M FY29 revenue target, and structural market tailwinds across three growth verticals.

Ready to Explore IDT Australia’s Path to $50M Revenue by FY29?

IDT Australia’s FY26 results mark a decisive turning point, with an 85% narrowing of EBITDA losses and 16.5% revenue growth across three high-growth manufacturing verticals, all underpinned by a fully funded $7M capability investment program.

Investors seeking to understand the full scope of IDT’s CDMO strategy, its Sanofi Preferred Vendor status, and its roadmap to profitability can explore the IDT Australia investor hub for the latest company updates and project details.